Abstracts tagged "patient preferences and rheumatoid arthritis"

Abstract Number: 2395 • 2014 ACR/ARHP Annual Meeting
Understanding Patient Preferences Associated with the Use of Therapies for Rheumatoid Arthritis: Results of a Conjoint Analysis
K. Saverno¹, A. Louder¹, A. Singh², J. Cappelleri³, A. Aten⁴, A. Koenig⁵ and M. Pasquale¹, ¹Comprehensive Health Insights Inc, Louisville, KY, ²Pfizer Inc, Groton, CT, ³Pfizer Inc, New York, NY, ⁴Humana Inc, Louisville, KY, ⁵Pfizer Inc, Collegeville, PA
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). Tofacitinib provides patients with a new oral alternative to biologic…
Abstract Number: 1568 • 2012 ACR/ARHP Annual Meeting
A Survey Study of Methotrexate Use by Rheumatologists and Their Patients with Rheumatoid Arthritis
Peter Nash¹ and Dave Nicholls², ¹University of Queensland, Brisbane, Australia, ²Coast Joint Care, Maroochydore, Australia
Background/Purpose: Methotrexate (MTX) is the anchor medication for the management of rheumatoid arthritis (RA); however there is limited patient-focused data available on the use of…
Abstract Number: 488 • 2012 ACR/ARHP Annual Meeting
Patient Preferences for Biologic Treatments in Rheumatoid Arthritis
Beenish Nafees¹, Andrew Lloyd¹, Carol L. Gaich², Julie Birt² and Rodney A. Hughes³, ¹Late Phase & Outcomes Research, Oxford Outcomes, Oxford, United Kingdom, ²Global Health Outcomes, Eli Lilly and Company, Indianapolis, IN, ³Rheumatology, St. Peters Hospital, Chertsey Surrey, United Kingdom
Background/Purpose: Patients with rheumatoid arthritis (RA) and their physicians face a range of treatment choices. The treatments that patients receive should be driven partly by…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].